Study refusal and exclusion from a randomized treatment study of generalized social phobia

Jonathan D. Huppert*, Martin E. Franklin, Edna B. Foa, Jonathan R.T. Davidson

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


We examine treatment exclusion and refusal rates as well as reasons for non-participation in a sub-sample of phone interviews conducted to determine eligibility for a randomized study of treatments for generalized social phobia (GSP). This study compared group comprehensive cognitive behavioral therapy (CCBT) to fluoxetine (FLU), placebo (PLA), or their combination. Results suggest that the major exclusion for the study was due to comorbid depression, followed by having a different diagnosis as primary. Patient refusal to enter the study was also common, with the most frequently reported reason being not wanting to take medication. Notably, few people who refused stated an objection to entering CCBT or PLA. These results suggest that there is a need to develop and evaluate a treatment for social anxiety with comorbid depression and to systematically study reasons for reluctance to take medication among individuals with GSP.

Original languageAmerican English
Pages (from-to)683-693
Number of pages11
JournalJournal of Anxiety Disorders
Issue number6
StatePublished - 2003
Externally publishedYes

Bibliographical note

Funding Information:
The study was supported by NIMH grant (MH49340) awarded to the Edna B. Foa. The authors would like to thank Nicole Dorfan and Connie Hamlin for their assistance in the collection of these data.


  • Effectiveness
  • Efficacy
  • Social anxiety
  • Treatment outcome


Dive into the research topics of 'Study refusal and exclusion from a randomized treatment study of generalized social phobia'. Together they form a unique fingerprint.

Cite this